← Back to Search

Advanced MRI Techniques for Li-Fraumeni Syndrome

N/A
Waitlist Available
Led By Andrea Doria, MD
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
LFS kindreds who either carry a known TP53 mutation or are obligate mutation carriers
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 2 years
Awards & highlights

Study Summary

This trial will use new techniques to MRI to see how well it can detect small tumors, and if it can tell the difference between cancerous and non-cancerous tumors.

Who is the study for?
This trial is for individuals with Li-Fraumeni Syndrome (LFS), a condition that greatly increases cancer risk. Participants must either carry a known TP53 mutation or be direct relatives of mutation carriers. They cannot take part if they have metal implants, pacemakers, or severe claustrophobia due to the MRI requirements.Check my eligibility
What is being tested?
The study is testing advanced MRI techniques including PET-MRI, Whole body STIR MRI, and DW-MRI to detect small tumors in LFS patients. It aims to determine how effective these methods are at identifying malignant versus benign tumors.See study design
What are the potential side effects?
There are generally no side effects associated with undergoing MRIs as they do not use ionizing radiation; however, some individuals may experience discomfort from lying still or anxiety due to the enclosed space.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My family has a known TP53 mutation, and I might carry it too.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluation of imaging traits on suspected tumors

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRI ImagingExperimental Treatment3 Interventions
Participants will be imaged with the standard MRI technique (STIR-MRI) and also new MRI techniques called "diffusion weighted" or "DW" MRI and Positron Emission Tomography (PET)-MRI. PET-MRI will be indicated if the results from the routine MRI and DW MRI are contradictory or if laboratory results do not correspond to the standard MRI and DW MRI results.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET-MRI
2018
N/A
~100
DW-MRI
2008
N/A
~50

Find a Location

Who is running the clinical trial?

The Hospital for Sick ChildrenLead Sponsor
686 Previous Clinical Trials
6,944,763 Total Patients Enrolled
Andrea Doria, MDPrincipal InvestigatorThe Hospital for Sick Children
2 Previous Clinical Trials
117 Total Patients Enrolled

Media Library

PET-MRI Clinical Trial Eligibility Overview. Trial Name: NCT03176836 — N/A
Li-Fraumeni Syndrome Research Study Groups: MRI Imaging
Li-Fraumeni Syndrome Clinical Trial 2023: PET-MRI Highlights & Side Effects. Trial Name: NCT03176836 — N/A
PET-MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT03176836 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities available for enrollment in this trial?

"Evidently, this investigation is no longer actively recruiting. It was first posted on June 20th 2016 and last updated November 13 2021; however, there are currently 1,388 other trials searching for participants."

Answered by AI
~4 spots leftby Jul 2025